Help Europe lead the wave in biotech innovation

The Call for Evidence on Biotech Act II is now open (deadline June 10th): a crucial opportunity for input the European biotech sector cannot afford to miss. With this next phase, the European Commission is focusing on industrial biotechnology and biomanufacturing, aiming to address bottlenecks such as insufficient market uptake, investment predictability and timelines, and fragmentation of the EU single market and regulation for bio-based products.
At hollandbio, we call for an ambitious and broad Biotech Act II that must work for all kinds of biotech products and biosolutions, as well as across the entire value chain, from early research to scale up and real world use. That requires an integrated approach to biotech policy, real investment in frontrunners, faster, predictable routes to market and market pull that helps innovations reach patients and consumers. This is the moment to act. So, make your voice heard before June 10th and help shape a Biotech Act II that lets biotech deliver, right here in Europe!